3378
HanX Biopharmaceuticals
HanX Biopharmaceuticals · 3378
Fra 1 stk.
Markedsdata leveret af TwelveData og Morningstar
INVESTER I HANX BIOPHARMACEUTICALS MED ENDAVU: Køb HanX Biopharmaceuticals ($3378) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i HanX Biopharmaceuticals, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a China-based clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative immunotherapies for cancers and autoimmune diseases. The company leverages its proprietary VersatiBody platform to advance a diversified pipeline, with lead candidate HX009, a bifunctional anti-PD-1/SIRPα antibody fusion protein designed to enhance immune response against tumors, currently in Phase 2 trials for advanced solid neoplasms. Key products also include HX301, a multi-targeted kinase inhibitor; HX044, a bispecific antibody targeting CD47 and CTLA4 for PD-1-resistant solid tumors in Phase 1/2; and HX008, a PD-1 antagonist monoclonal antibody. Focused on immuno-oncology pathways, Hanx Biopharmaceuticals employs monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates to address unmet needs in oncology and immunology. Founded in 2014 and headquartered in Wuhan, the firm plays a role in advancing next-generation precision therapies within the global biotechnology sector.
